---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-008178"
form_type: "8-K"
ticker: "ATAI"
cik: "0002081043"
company_name: "AtaiBeckley Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T19:06:32.899091+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026

## Summary
- Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.
- Net loss $544.8M in Q4, $660M full year; includes $530M non-cash IP R&D charge from Beckley Psytech combo.
- BPL-003 Phase 3 pivotal program (ReConnection-1 and -2) initiation on track for Q2 2026; topline data early 2029.
- EMP-01 Phase 2a met primary safety; showed 11.85-point LSAS reduction vs placebo (p=0.036).
- VLS-01 Phase 2 Elumina topline data readout anticipated H2 2026.

## SEC filing metadata
- accession: 0001140361-26-008178
- form_type: 8-K
- ticker: ATAI
- cik: 0002081043
- company_name: AtaiBeckley Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2081043/000114036126008178/0001140361-26-008178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2081043/000114036126008178/ef20066741_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-008178
- JSON: https://secwatch.observer/filing/0001140361-26-008178.json
- Plain text: https://secwatch.observer/filing/0001140361-26-008178.txt

## Key facts
- Earnings Releases
  AtaiBeckley Inc. reported financial results for fourth quarter and year ended December 31, 2025.
  - Period: fourth quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 6, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate and clinical update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2081043/000114036126008178/0001140361-26-008178-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.